We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Zalunfiban is an investigational platelet inhibitor that ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...

Scientists from Finland and the UK have uncovered groundbreaking evidence that heart attacks may be triggered by infectious processes rather than just cholesterol and lifestyle factors. Hidden ...

A pioneering study by researchers from Finland and the UK has demonstrated for the first time that myocardial infarction may be an infectious disease. This discovery challenges the conventional ...

Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...

When it comes to delivering timely treatment for patients experiencing myocardial infarction (MI), many hospitals are continuing to fall short of national guidelines, new research showed. Benchmarks ...

1 Department of Cardiology, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, China 2 Department of Cardiology, ...

Cardiovascular disease is by far the most common cause of death worldwide, and myocardial infarction is the most common acute event. For those who survive a myocardial infarction, the risk of a new ...